MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Trends Pharmacol Sci. 2023 Nov;44(11):786-801. doi: 10.1016/j.tips.2023.08.007. Epub 2023 Sep 29.
Targeted protein degradation (TPD) is an emerging modality for research and therapeutics. Most TPD approaches harness cellular ubiquitin-dependent proteolytic pathways. Proteolysis-targeting chimeras (PROTACs) and molecular glue (MG) degraders (MGDs) represent the most advanced TPD approaches, with some already used in clinical settings. Despite these advances, TPD still faces many challenges, pertaining to both the development of effective, selective, and tissue-penetrant degraders and understanding their mode of action. In this review, we focus on progress made in addressing these challenges. In particular, we discuss the utility and application of recent proteomic approaches as indispensable tools to enable insights into degrader development, including target engagement, degradation selectivity, efficacy, safety, and mode of action.
靶向蛋白降解(TPD)是一种新兴的研究和治疗模式。大多数 TPD 方法利用细胞内泛素依赖性蛋白水解途径。蛋白水解靶向嵌合体(PROTAC)和分子胶(MG)降解剂(MGD)代表了最先进的 TPD 方法,其中一些已经在临床环境中使用。尽管取得了这些进展,但 TPD 仍然面临许多挑战,涉及到有效、选择性和组织穿透性降解剂的开发以及对其作用模式的理解。在这篇综述中,我们重点介绍了在应对这些挑战方面取得的进展。特别是,我们讨论了最近蛋白质组学方法的实用性和应用,这些方法是深入了解降解剂开发的不可或缺的工具,包括靶标结合、降解选择性、疗效、安全性和作用模式。